Skaara TR et al., 2025-10-14: Norwegian case report of a cancer patient on immunotherapy who developed a tenfold rise in cholestatic liver enzymes after taking 2 g of veterinary fenbendazole daily for a week; biopsy showed lobular and portal inflammation and the parameters fell spontaneously two weeks after admission.
We were informed that the patient had ingested 2 g daily of Fenbendazole, a veterinary anti-helminthic drug, during the preceding week as an alternative cancer treatment.
Abstract
Skaara TR et al., 2025-10-14: Norwegian case report of a cancer patient on immunotherapy who developed a tenfold rise in cholestatic liver enzymes after taking 2 g of veterinary fenbendazole daily for a week; biopsy showed lobular and portal inflammation and the parameters fell spontaneously two weeks after admission. Study type: single case report, n=1, Norway (Oslo University Hospital). Dose as published: 2 g daily for one week, oral. Other treatment: immunotherapy (checkpoint inhibitor) two weeks earlier. Outcome: cholestatic parameters fell spontaneously two weeks after admission; liver biopsy showed lobular and portal inflammation; fenbendazole named the suspected cause. Funding and conflicts: not stated in the abstract. Article in Norwegian; the title in the record is the journal's English translation of '[Cholestasis following use of fenbendazole as alternative cancer treatment]'. Comparator: none. Also filed as FBE-26 (claims C2, C3). Study type: case report.
